Hangzhou, China, May 21, 2025 — WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”), a Chinese medical device supplier operating through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd., and its other Chinese subsidiaries, has announced the pricing of its registered offering (the “Offering”). The offering consists of 10,000,000 ordinary units (the “Ordinary Units”) or, alternatively, pre-funded units (the “Pre-funded Units”), priced at $0.50 per Ordinary Unit and $0.4995 per Pre-funded Unit. The number of Ordinary Units offered will decrease by one for each Pre-funded Unit sold.

Each Ordinary Unit includes one Class A ordinary share (par value $0.0005), one Series A warrant to purchase one Class A Ordinary Share at $1.00 (a “Series A Warrant”), and one Series B warrant to purchase one Class A Ordinary Share at $1.00 (a “Series B Warrant”). Each Pre-funded Unit contains one pre-funded warrant to purchase one Class A Ordinary Share (a “Pre-funded Warrant”), one Series A Warrant, and one Series B Warrant. The Pre-funded Warrants, Series A Warrants, and Series B Warrants are exercisable immediately upon issuance. The Pre-funded Warrants expire upon full exercise, the Series A Warrants expire in 12 months, and the Series B Warrants expire in 3 months.

The Company anticipates gross proceeds of US$5.0 million from the Offering, before accounting for underwriting discounts and other related expenses.

The Company intends to use the proceeds from the Offering to upgrade production equipment, invest in research and development within its PRC subsidiaries, hire experienced personnel to enhance internal controls and compliance with U.S. GAAP and the Sarbanes-Oxley Act of 2002, and for general working capital and corporate purposes.

The Offering is being conducted on a firm commitment basis, with Univest Securities, LLC serving as the sole book-running manager.

These securities are being offered pursuant to a registration statement on Form F-1 (File No. 333-284006), as amended (the “Registration Statement”), previously filed with and declared effective by the SEC. This press release is not an offer to sell or a solicitation of an offer to buy securities, nor will there be any sale of these securities in any jurisdiction where such offer, solicitation, or sale would be unlawful before registration or qualification under the applicable securities laws. The Offering is being made only through a prospectus that is part of the effective Registration Statement. The final prospectus will be filed with the SEC and made available on its website at . Electronic copies of the final prospectus, when available, can be obtained from Univest Securities, LLC at or by calling +1 (212) 343-8888.

About WORK Medical Technology Group LTD

WORK Medical Technology Group LTD, via its subsidiary Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, supplies medical devices, developing and manufacturing Class I and II medical devices and selling Class I and II disposable medical devices through its Chinese operating subsidiaries. The company’s product portfolio includes 21 products, such as customized and multifunctional masks and other medical consumables. These products are sold across 34 provincial-level administrative regions in China, with 15 products sold in over 30 countries globally. The Company holds several quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration, enabling their sale in the U.S. market. Additional information can be found on the Company’s website: .

Forward-Looking Statements

This press release includes forward-looking statements protected by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are often identified by terms like “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and similar expressions. Any statements herein that do not relate to historical facts are considered forward-looking statements.

These forward-looking statements reflect the Company’s current expectations, estimates, and projections as of this release date and are subject to various risks and uncertainties. These factors could cause actual results to differ materially and adversely from those expressed or implied in the statements. These risks include, but are not limited to, the completion of the proposed Offering on the expected terms or at all, market conditions, and the satisfaction of standard closing conditions. While the Company believes these expectations are reasonable, it cannot guarantee their accuracy. Investors are cautioned that actual results may differ significantly from anticipated results and are encouraged to review other factors that could impact future performance, as detailed in the Company’s annual report on Form 20-F for the fiscal year ended September 30, 2024, the Registration Statement, and other filings with the SEC. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

For more information, please contact:

WORK Medical Technology Group LTD
Investor Relations Department
Email:

Ascent Investor Relations LLC
Tina Xiao
Phone: +1 646-932-7242
Email:

“`